Label: OXACILLIN- oxacillin injection, powder, for solution

  • NDC Code(s): 0781-9110-15, 0781-9110-92, 0781-9112-15, 0781-9112-92
  • Packager: Sandoz Inc
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 5, 2015

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    For Intravenous Injection Only

    In ADD-Vantage® Drug Delivery System

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection and other antibacterial drugs, oxacillin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

    Close
  • DESCRIPTION

    Oxacillin for Injection, USP ADD-Vantage® is a semisynthetic penicillin antibiotic derived from the penicillin nucleus, 6-amino-penicillanic acid. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). It is the sodium salt in a parenteral dosage form for intravenous use.

    Each vial of oxacillin for injection, USP contains oxacillin sodium monohydrate equivalent to 1 gram or 2 grams of oxacillin. The sodium content is 63.5 mg (2.8 mEq) per gram of oxacillin. The product is buffered with 19 mg dibasic sodium phosphate per gram of oxacillin.

    oxacillin sodium chemical structure

    The chemical name of oxacillin sodium is 4-Thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl) carbonyl] amino]-7-oxo-,monosodium salt, monohydrate, [2S(2α,5α,6β)]. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The molecular formula of oxacillin sodium is C19H18N3NaO5S•H2O. The molecular weight is 441.43.

    Close
  • CLINICAL PHARMACOLOGY

    Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes.

    Oxacillin sodium, with normal doses, has insignificant concentrations in the cerebrospinal and ascitic fluids. It is found in therapeutic concentrations in the pleural, bile, and amniotic fluids.

    Oxacillin sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for oxacillin is about 0.5 hours. Nonrenal elimination includes hepatic inactivation and excretion in bile.

    Oxacillin sodium binds to serum protein, mainly albumin. The degree of protein binding reported varies with the method of study and the investigator, but generally has been found to be 94.2 ± 2.1%.

    Probenecid blocks the renal tubular secretion of penicillins. Therefore, the concurrent administration of probenecid prolongs the elimination of oxacillin and, consequently, increases the serum concentration.

    Intramuscular injections give peak serum levels 30 minutes after injection. A 250 mg dose gives a level of 5.3 mcg/mL while a 500 mg dose peaks at 10.9 mcg/mL. Intravenous injection gives a peak about 5 minutes after the injection is completed. Slow IV dosing with 500 mg gives a 5 minute peak of 43 mcg/mL with a half-life of 20 to 30 minutes.

    Microbiology

    Mode of Action

    Penicillinase-resistant penicillins exert a bactericidal action against penicillin susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.

    Mechanism of Resistance

    Resistance to penicillins may be mediated by destruction of the beta-lactam ring by a beta-lactamase, altered affinity of penicillin for target, or decreased penetration of the antibiotic to reach the target site.

    Cross Resistance

    Resistance to oxacillin (or cefoxitin) implies resistance to all other beta-lactam agents, except newer agents with activity against methicillin-resistant Staphylococcus aureus.

    Susceptibility Test Methods

    When available, the clinical microbiology laboratory should provide of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antibacterial drug for treatment.

    Dilution techniques

    Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method1,2 (broth and/or agar). The MIC values should be interpreted according to the criteria in Table 1.

    Diffusion techniques

    Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method.2,3 It has been determined that the most accurate method to test the susceptibility of microorganisms to penicillinase resistant penicillins, including oxacillin, by disk diffusion is achieved using disks impregnated with 30 mcg cefoxitin. Interpretation involves correlation of the diameter obtained with the cefoxitin disk test with the MIC for oxacillin.2 Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 microgram cefoxitin disk should be interpreted according to the following criteria in Table 1.

    Table 1: Susceptibility Test Interpretive Criteria For Oxacillin
    Pathogen Antimicrobial
    Agent
    Disk
    Content
    Disk Diffusion
    Zone Diameter
    (mm)
    *
    Minimum Inhibitory
    Concentrations (mcg/mL)
    S I R S I R
    S=susceptible, I=intermediate, R-resistant
    *
    In most staphylococcal isolates, oxacillin resistance is mediated by mecA, encoding the penicillin binding protein 2a (PBP2a, also called PBP2’). Isolates that test positive for mecA or PBP2a should be reported as oxacillin resistant. 2
    If both cefoxitin and oxacillin are tested against S. aureus or S. lugdenensis , and either result is resistant, the organism should be reported as oxacillin resistant. 2
    Cefoxitin is used as a surrogate for oxacillin; report oxacillin susceptible or resistant based on the cefoxitin result. 2
    §
    Oxacillin MIC interpretive criteria may overcall resistance for some coagulase-negative staphylococci (CoNS), because some non- S. epidermidis strains for which the oxacillin MICs are 0.5 to 2 mcg/mL lack mecA . For serious infections with CoNS other than S. epidermidis, testing for mecA or for PBP 2a or with cefoxitin disk diffusion may be appropriate for strains for which the oxacillin MICs are 0.5 to 2 mcg/mL. 2

    Staphylococcus aureus and S. lugdenensis

    Oxacillin

    -

    30 mcg cefoxitin

    -

    ≥22

    -

    -

    -

    ≤21

    ≤2
    (oxacillin)
    ≤4
    (cefoxitin)

    -

    -

    ≥4
    (oxacillin)
    ≥8
    (cefoxitin)

    Coagulase-negative staphylococci except S. lugdenensis

    Oxacillin§

    -

    30 mcg cefoxitin

    -

    ≥25

    -

    -

    -

    ≤24

    ≤0.25

    -

    -

    -

    ≥0.5

    -

    A report of “Susceptible” indicates that the antimicrobial is likely to inhibit the growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

    Quality Control

    Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2,3 Standard oxacillin powder should provide the following range of MIC values1 noted in Table 2. For the diffusion technique using the 30 mcg cefoxitin disk, the criteria in Table 2 should be achieved.

    Table 2: Acceptable Quality Control Ranges for Susceptibility Testing
    Quality Control
    Organism
    Minimal Inhibitory
    Concentration
    (mcg/mL)
    Disk Diffusion
    Zone Diameters (mm)
    ATCC= American Type Culture Collection
    *
    Despite the lack of reliable disk diffusion interpretive criteria for S. pneumoniae with certain beta-lactams, Streptococcus pneumoniae ATCC® 49619 is the strain designated for QC of all disk diffusion tests with all Streptococcus spp.
    Deterioration of the oxacillin disk content is best assessed with QC organism S. aureus ATCC® 25923, with an acceptable zone diameter for 18-24.

    Enterococcus faecalis
    ATCC® 29212

    8-32

    -

    Staphylococcus aureus
    ATCC® 25923

    -

    18-24

    Staphylococcus aureus
    ATCC® 29213

    0.12-0.5

    -

    Streptococcus pneumoniae
    ATCC® 49619*

    -

    ≤12

    Close
  • INDICATIONS AND USAGE

    Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (See CLINICAL PHARMACOLOGY: Susceptibility Test Methods).

    Oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Oxacillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus, therapy should not be continued with oxacillin.

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin for Injection, USP and other antibacterial drugs, Oxacillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Close
  • CONTRAINDICATIONS

    A history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

    Close
  • WARNINGS

    Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015 and 0.04 percent. Anaphylactic shock resulting in death has occurred in approximately 0.002 percent of the patients treated.

    When oxacillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, oxacillin should be discontinued and appropriate therapy instituted.

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including oxacillin for injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    Close
  • PRECAUTIONS

    General

    Oxacillin should generally not be administered to patients with a history of sensitivity to any penicillin.

    Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy.

    The use of antibiotics may result in overgrowth of nonsusceptible organisms. If new infections due to bacteria or fungi occur, the drug should be discontinued and appropriate measures taken.

    Prescribing Oxacillin for Injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    Laboratory Tests

    Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should be performed (See CLINICAL PHARMACOLOGY: Microbiology). In the treatment of suspected staphylococcal infections, therapy should be changed to another active agent if culture tests fail to demonstrate the presence of staphylococci.

    Periodic assessment of organ system function including renal, hepatic, and hematopoietic should be made during prolonged therapy with oxacillin.

    Blood cultures, white blood cell, and differential cell counts should be obtained prior to initiation of therapy and at least weekly during therapy with oxacillin.

    Periodic urinalysis, blood urea nitrogen, and creatinine determinations should be performed during therapy with oxacillin and dosage alterations should be considered if these values become elevated. If any impairment of renal function is suspected or known to exist, a reduction in the total dosage should be considered and blood levels monitored to avoid possible neurotoxic reactions.

    AST (SGOT) and ALT (SGPT) values should be obtained periodically during therapy to monitor for possible liver function abnormalities.

    Drug Interactions

    Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.

    Oxacillin blood levels may be increased and prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillins.

    Oxacillin-probenecid therapy should be limited to those infections where very high serum levels of oxacillin are necessary.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term animal studies have been conducted with these drugs.

    Studies on reproduction (nafcillin) in rats and rabbits reveal no fetal or maternal abnormalities before conception and continuously through weaning (one generation).

    Pregnancy

    Teratogenic Effects

    Pregnancy Category B

    Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to the penicillinase-resistant penicillins. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate or well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Nursing Mothers

    Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman.

    Pediatric Use

    Because of incompletely developed renal function in pediatric patients, oxacillin may not be completely excreted, with abnormally high blood levels resulting. Frequent blood levels are advisable in this group with dosage adjustments when necessary. All pediatric patients treated with penicillins should be monitored closely for clinical and laboratory evidence of toxic or adverse effects. Safety and effectiveness in pediatric patients have not been established.

    Geriatric Use

    Clinical studies of oxacillin for injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    Oxacillin for Injection contains 63.5 mg (2.8 mEq) of sodium per gram of oxacillin. At the usual recommended doses, patients would receive between 63.5 and 381 mg/day (2.8 and 16.8 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.

    Information for Patients

    Patients should be counseled that antibacterial drugs including Oxacillin for Injection, USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Oxacillin for Injection, USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Oxacillin for Injection, USP or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

    Close
  • ADVERSE REACTIONS

    Body as a Whole

    The reported incidence of allergic reactions to penicillin ranges from 0.7 to 10 percent (see WARNINGS). Sensitization is usually the result of treatment but some individuals have had immediate reactions when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines.

    Two types of allergic reactions to penicillins are noted clinically, immediate and delayed.

    Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angioneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse, and death. Such immediate anaphylactic reactions are very rare (see WARNINGS) and usually occur after parenteral therapy but have occurred in patients receiving oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus, and fever. Although laryngeal edema, laryngospasm, and hypotension occasionally occur, fatality is uncommon.

    Delayed allergic reactions to penicillin therapy usually occur after 48 hours and sometimes as late as 2 to 4 weeks after initiation of therapy.

    Manifestations of this type of reaction include serum sickness-like symptoms (i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and various skin rashes. Nausea, vomiting, diarrhea, stomatitis, black or hairy tongue, and other symptoms of gastrointestinal irritation may occur, especially during oral penicillin therapy.

    Nervous System Reactions

    Neurotoxic reactions similar to those observed with penicillin G may occur with large intravenous doses of oxacillin especially with patients with renal insufficiency.

    Urogenital Reactions

    Renal tubular damage and interstitial nephritis have been associated with the administration of oxacillin. Manifestations of this reaction may include rash, fever, eosinophilia, hematuria, proteinuria, and renal insufficiency. Nephropathy induced by penicillins does not appear to be dose-related and is generally reversible upon prompt discontinuation of therapy.

    Gastrointestinal Reactions

    Pseudomembranous colitis has been reported with the use of oxacillin. The onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

    Metabolic Reactions

    Agranulocytosis, neutropenia, and bone marrow depression have been associated with the use of oxacillin. Hepatotoxicity, characterized by fever, nausea, and vomiting associated with abnormal liver function tests, mainly elevated SGOT levels, has been associated with the use of oxacillin.

    To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Close
  • OVERDOSAGE

    The signs and symptoms of oxacillin overdosage are those described in the ADVERSE REACTIONS section. If signs or symptoms occur, discontinue use of the medication, treat symptomatically, and institute appropriate supportive measures.

    Close
  • DOSAGE AND ADMINISTRATION

    Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should always be performed. Duration of therapy varies with the type of severity of infection as well as the overall condition of the patient, therefore it should be determined by the clinical and bacteriological response of the patient. In severe staphylococcal infections, therapy with oxacillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. Treatment of endocarditis and osteomyelitis may require a longer duration of therapy.

    With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.

    Recommended Dosages for Oxacillin Sodium for Injection, USP

    In ADD-Vantage® System: For Intravenous Use Only

    Adults: 1 to 6 grams per 24-hour period.

    NOTE: For doses smaller than 1 gram use the conventional vial. Insert for conventional vial lists dosages for infants and children.

    Directions for use

    Oxacillin for Injection Vials in the ADD-Vantage® Drug Delivery System are for intravenous use only and are to be used with ADDVantage® diluent containers of 0.9% Sodium Chloride Injection, USP, 50 mL and 100 mL, or 5% Dextrose Injection, USP, 50 mL and 100 mL.

    Reconstitute ADD-Vantage® vials as directed in the INSTRUCTIONS FOR USE section.

    Only 0.9% Sodium Chloride Injection, USP, and 5% Dextrose Injection, USP, are available for use in the ADD-Vantage® Delivery System for intravenous infusion of oxacillin sodium. The concentration of the antibiotic should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of oxacillin is administered before the drug loses its stability in the solution in use.

    If another agent is used in conjunction with oxacillin therapy, it should not be physically mixed with oxacillin but should be administered separately.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

    Do not add supplementary medication to oxacillin for injection, USP.

    INSTRUCTIONS FOR USE

    To Open Diluent Container:

    Peel overwrap from the corner and remove container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

    To Assemble Vial and Flexible Diluent Container:

    (Use Aseptic Technique)

    1.
    Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:
    a. To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (SEE FIGURE 1), then pull straight up to remove the cap. (SEE FIGURE 2.)
    NOTE: Do not access vial with syringe.

    Figures 1 and 2

    b. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (SEE FIGURE 3.)
    2.
    Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180°) after the first audible click. (SEE FIGURE 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go. NOTE: Once vial is seated, do not attempt to remove. (SEE FIGURE 4.)
    3.
    Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.
    4.
    Label appropriately.
    Figures 3 and 4

    To Prepare Admixture:

    1.
    Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.
    2.
    With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (SEE FIGURE 5.)
    3.
    Pull the inner cap from the drug vial. (SEE FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.
    4.
    Mix container contents thoroughly and use within the specified time.
    Figures 5 and 6

    Preparation for Administration:

    (Use Aseptic Technique)

    1.
    Confirm the activation and admixture of vial contents.
    2.
    Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
    3.
    Close flow control clamp of administration set.
    4.
    Remove cover from outlet port at bottom of container.
    5.
    Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    NOTE: See full directions on administration set carton.
    6.
    Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
    7.
    Squeeze and release drip chamber to establish proper fluid level in chamber.
    8.
    Open flow control clamp and clear air from set. Close clamp.
    9.
    Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
    10.
    Regulate rate of administration with flow control clamp.

    WARNING: Do not use flexible container in series connections.

    At concentrations ranging from 10 to 40 mg/mL in 0.9% Sodium Chloride Injection, USP, Oxacillin will have utility times of 4 days at room temperature (25°C).

    In 5% Dextrose Injection, USP, at concentrations from 10 to 40 mg/mL Oxacillin will have utility times of 6 hours at room temperature (25°C).

    Close
  • HOW SUPPLIED/STORAGE AND HANDLING

    Oxacillin for Injection, USP ADD-Vantage® for intravenous use contains oxacillin sodium equivalent to 1 or 2 grams oxacillin per vial.

    NDC 0781-9110-92 - 1 gram ADD-Vantage® Vial, packed in 10s

    NDC 0781-9112-92 - 2 gram ADD-Vantage® Vial, packed in 10s

    Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

    Close
  • REFERENCES

    1.
    Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. CLSI Document M07-A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
    2.
    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement. CLSI Document M100-S25. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
    3.
    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Twelfth Edition. CLSI Document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

    ADD-Vantage® is a trademark of Hospira Inc.

    NOVAPLUS is a registered trademark of Novation, LLC.

    12-2015M

    46176054

    Manufactured in Austria by Sandoz GmbH

    for Sandoz Inc., Princeton, NJ 08540

    Product of Italy

    Close
  • 1 gram Label

    NDC 0781-9110-92 Rx ONLY

    Oxacillin

    for Injection, USP

    Case Qty.: 10 ADD-Vantage® Vials

    Buffered – for IV use

    1 gram

    N+ and NOVAPLUS are registered

    trademarks of Novation, LLC

    NOVAPLUS®

    Oxacillin for Injection 1 gram Label
    Close
  • 2 gram Label

    NDC 0781-9112-92 Rx ONLY

    Oxacillin

    for Injection, USP

    CASE QTY.: 10 ADD-Vantage® vials

    Buffered – for IV use

    2 grams

    N+ and NOVAPLUS are registered

    trademarks of Novation, LLC

    NOVAPLUS®

    Oxacillin for Injection 2 gram Label
    Close
  • INGREDIENTS AND APPEARANCE
    OXACILLIN 
    oxacillin injection, powder, for solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0781-9110
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OXACILLIN SODIUM (UNII: G0V6C994Q5) (OXACILLIN - UNII:UH95VD7V76) OXACILLIN 1 g
    Inactive Ingredients
    Ingredient Name Strength
    SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0781-9110-92 10 in 1 PACKAGE
    1 NDC:0781-9110-15 1 in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA062737 12/23/1986
    OXACILLIN 
    oxacillin injection, powder, for solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0781-9112
    Route of Administration INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OXACILLIN SODIUM (UNII: G0V6C994Q5) (OXACILLIN - UNII:UH95VD7V76) OXACILLIN 2 g
    Inactive Ingredients
    Ingredient Name Strength
    SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0781-9112-92 10 in 1 PACKAGE
    1 NDC:0781-9112-15 1 in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA062737 12/23/1986
    Labeler - Sandoz Inc (110342024)
    Close